Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046044/SGN-35C in Adults With Advanced Malignancies
NCT06254495Phase 1Terminated
- Sponsor
- Pfizer
- Start
- May 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of PF-08046044 in Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL) and 1 more, sponsored by Pfizer. Primary endpoints: Number of participants with adverse events at 1 year, Number of participants with laboratory abnormalities at 1 year and 3 more. Started May 2024; status: terminated.
02
Drugs
PF-08046044
03
Conditions
Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT06254495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254495.